← Back to patent-cliff list
Elamipretide
Tier C — Watch / tradeElamipretide
-
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Mitocliondrial permeability transition pore, Free radicals
Brand：Bendavia, Forzinity, Ocuvia
Indications (approved)：巴氏症候群
Regional status
US
Approved
2025-09-19
EU
Phase III
2017-10-09
China
Phase I
2026-08-11
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Elamipretide?
Approved indications include: 巴氏症候群.
When does the Elamipretide patent expire?
No public expiry year is available for Elamipretide yet; this page updates once verified.
How do I get a quote for Elamipretide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01